WebCytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Web19 de nov. de 2010 · Cytarabine has been used in combination with etoposide (CYVE) as a salvage therapy for patients who have been refractory to or relapsed after HD-MTX-based regimens (Soussain C et al, J. Clin. Oncol. 2001; Soussain C et al, J. Clin. Oncol. 2008).
A historical perspective on the development of the cytarabine …
Web31 de jul. de 2024 · Background: The role of cytarabine on newly diagnosed primary central nervous system lymphoma (PCNSL) remains controversial. The present study mainly aimed to assess the efficacy and safety of cytarabine in the induction treatment of PCNSL.Methods: We systematically searched PubMed, Embase, and the Cochrane … WebCytarabine ≤ 1,000 mg/m² Decitabine Docetaxel -ejfv Eribulin Etoposide Fluorouracil Gemcitabine Gemcitabine ozogamicin Inotuzumab ozogamicin Ixabepilone Methotrexate … barema 588
Cytarabine - indikasi, dosis, interaksi dan efek samping - Alomedika
Web29 de nov. de 2024 · The median number of Cytarabine consolidation cycles was 2 (range 1-4 cycles) with Cytarabine total dose per cycle ranging between 6 gr/m2-18 gr/m2. The median cumulative dose from all cycles of consolidation was 18 gr/m2. We considered a cumulative dose ≤18 gr/m2 to be "low intensity (LI)" and > 18 gr/m2 "high intensity (HI)". WebDoxorubicin Melphalan Cytarabine Daunorubicin Anthracyclines (other): Etoposide phosphate Epirubicin Liposomal doxorubicin Gemcitabine Idarubicin Liposomal Daunorubicin Fludarabine Others (antibiotics) Mitoxantrone Interferons Dactinomycin Topoisomerase II inhibitors Interleukin-2 Mitomycin C Etoposide Methotrexate … WebThis is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC. Approval was based on data from Study CLTR0310-301 (NCT01696084), a randomized … barema 581